Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study

The Lancet

Volumn 388, Issue 10039, 2016, Pages 45-54

  Tarantino, Michael D ^a   Bussel, James B ^b   Blanchette, Victor S ^c   Despotovic, Jenny ^d   Bennett, Carolyn ^e   Raj, Ashok ^f   Williams, Bronwyn ^g   Beam, Donald ^h   Morales, Jaime ⁱ   Rose, Melissa J ^j   Carpenter, Nancy ^k   Nie, Kun ^l   Eisen, Melissa ^l  

^a UNIVERSITY OF ILLINOIS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d Texas Children's Hematology Center   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SCRI   (United States)

^g LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^h Children's Medical Center   (United States)

ⁱ LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^j THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^k AMGEN LTD   (United Kingdom)

^l AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROMIPLOSTIM; FC RECEPTOR; HYBRID PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ABSENCE; ADOLESCENT; ARTICLE; AUSTRALIA; BITE; BLEEDING; BRONCHIOLITIS; CANADA; CHILD; CONTROLLED STUDY; CONTUSION; DIARRHEA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FEVER; GINGIVA BLEEDING; HEADACHE; HEMATURIA; HUMAN; IMMUNOPATHOLOGY; INTERACTIVE VOICE RESPONSE SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTIC SYNDROME; ORAL BLEEDING; OROPHARYNX PAIN; PETECHIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; AGONISTS; BLOOD; CLINICAL TRIAL; INFANT; PRESCHOOL CHILD; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; MALE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84963878367     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00279-8     Document Type: Article

References (31)

1. 1 Chalmers, S, Tarantino, MD, Romiplostim as a treatment for immune thrombocytopenia: a review. J Blood Med 6 (2015), 37–44.
2. 2 Terrell, DR, Beebe, LA, Vesely, SK, Neas, BR, Segal, JB, George, JN, The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85 (2010), 174–180.
3. 3 Provan, D, Stasi, R, Newland, AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115 (2010), 168–186.
4. 4 Neunert, C, Noroozi, N, Norman, G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 13 (2015), 457–464.
5. 5 Neunert, C, Lim, W, Crowther, M, Cohen, A, Solberg, L Jr, Crowther, MA, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117 (2011), 4190–4207.
6. 6 Bennett, CM, Rogers, ZR, Kinnamon, DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107 (2006), 2639–2642.
7. 7 Parodi, E, Rivetti, E, Amendola, G, et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol 144 (2009), 552–558.
8. 8 Wang, B, Nichol, JL, Sullivan, JT, Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76 (2004), 628–638.
9. 9 Broudy, VC, Lin, NL, AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25 (2004), 52–60.
10. ® (romiplostim) United States Prescribing Information. http://pi.amgen.com/united_states/nplate/nplate_pi_hcp_english.pdf (accessed Jan 8, 2016).
11. 11 Bussel, JB, Buchanan, GR, Nugent, DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 118 (2011), 28–36.
12. 12 Elalfy, MS, Abdelmaksoud, AA, Eltonbary, KY, Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol 90 (2011), 1341–1344.
13. 13 Pasquet, M, Aladjidi, N, Guiton, C, et al. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br J Haematol 164 (2014), 266–271.
14. 14 Ramaswamy, K, Hsieh, L, Leven, E, Thompson, MV, Nugent, D, Bussel, JB, Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr 165 (2014), 600–605.
15. 15 Bussel, JB, Hsieh, L, Buchanan, GR, et al. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer 62 (2014), 208–213.
16. 16 Bussel, JB, de Miguel, PG, Despotovic, JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2 (2015), e315–e325.
17. 17 Grainger, JD, Locatelli, F, Chotsampancharoen, T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386 (2015), 1649–1658.
18. 18 George, JN, Woolf, SH, Raskob, GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88 (1996), 3–40.
19. 19 Rodeghiero, F, Stasi, R, Gernsheimer, T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113 (2009), 2386–2393.
20. 20 Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf (accessed Feb 19, 2015).
21. 21 Klaassen, RJ, Blanchette, VS, Barnard, D, et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools. J Pediatr 150 (2007), 510–515.
22. 22 Neunert, CE, Buchanan, GR, Imbach, P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 112 (2008), 4003–4008.
23. 23 Kuhne, T, Berchtold, W, Michaels, LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 96 (2011), 1831–1837.
24. 24 Neunert, CE, Buchanan, GR, Imbach, P, et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 121 (2013), 4457–4462.
25. 25 Medeiros, D, Buchanan, GR, Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr 133 (1998), 334–339.
26. 26 Imbach, P, Kuhne, T, Muller, D, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 46 (2006), 351–356.
27. 27 Buchanan, GR, Adix, L, Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 141 (2002), 683–688.
28. 28 Butros, LJ, Bussel, JB, Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol 25 (2003), 660–664.
29. 29 Lilleyman, JS, Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology. Arch Dis Child 71 (1994), 251–253.
30. 30 Psaila, B, Petrovic, A, Page, LK, Menell, J, Schonholz, M, Bussel, JB, Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 114 (2009), 4777–4783.
31. 31 Mathias, SD, Li, X, Eisen, M, et al. A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with immune thrombocytopenia and associated burden in their parents. Pediatr Blood Cancer, 2016 in press.